AP 001 - Anida Pharma
Alternative Names: AP-001 - Anida Pharma; Neuroprotectin D1 - Anida Pharma; NPD1 - Anida Pharma; Protectin D1Latest Information Update: 25 Jun 2023
At a glance
- Originator Anida Pharma
- Developer ALS Therapy Development Institute; Anida Pharma
- Class Docosahexaenoic acids; Small molecules
- Mechanism of Action Apoptosis inhibitors; MTOR protein modulators; Proto-oncogene protein c-akt modulators; Proto-oncogene protein c-bcl-2 modulators; Reactive oxygen species inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Age-related macular degeneration; Hearing loss; Keratitis; Retinopathy of prematurity
- Research Retinitis pigmentosa
- Discontinued Amyotrophic lateral sclerosis; Parkinson's disease
Most Recent Events
- 25 Jun 2023 AP 001 is still in preclinical trials for Hearing loss in USA
- 25 Jun 2023 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (unspecified route)
- 25 Jun 2023 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route)